Go To Global Site
Welcome to UCB in the United States

Jul

22

UCB Statement on Non-Radiographic Axial Spondyloarthritis Diagnostic Code Update

Today, UCB issued the following statement jointly from Camille Lee, Head of U.S. Immunology, and Jeff Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee (a subcommittee of the U.S. Centers for Disease Control and Prevention) to endorse and make public that non-radiographic axial spondyloarthritis (nr-axSpA) will be formally indexed to ICD-10 sub category M46.8; these changes will be effective for diagnoses starting October 1, 2020 and more information is available on the Centers for Medicare & Medicaid Service (CMS) website which outlines the specific coding changes in greater detail:

Jul

16

Finding Stability in the Storm

At UCB, patients are at the heart of everything we do. Read more from Brad Chapman, U.S. Head of Internal Operations and West Ecosystem - Neurology, on how our agile ways of working are helping us keep our commitment to patients, physicians, and the communities we serve in a work-from-home world.

Jul

08

UCB Welcomes First Class of Virtual Interns

Despite the unprecedented events stemming from the novel coronavirus, we are pleased to continue our mission of investing in the next generation of the work force by welcoming 18 student interns to our first virtual internship program.

Jul

07

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease

Jun

29

We are Stronger When We Respond to COVID-19 Together

At UCB, we know we’re stronger when we work together. Read more from Patty Fritz, VP of U.S. Corporate Affairs, about how UCB adapted in response to the COVID-19 pandemic to met the new unique needs of the patients, caregivers, health care providers, and health systems we’re committed to serving.

Jun

25

Living with Myasthenia Gravis - Jennifer's Story

For MG Awareness Month, we're spreading awareness about myasthenia gravis (MG) by showcasing Jennifer's inspiring story about living with the disease. Hear about her experience and advice for others living with MG by watching the video below.

Jun

24

UCB Announces New Data from its Epilepsy Portfolio Presented on the American Academy of Neurology Virtual Platform

Six poster presentations highlight clinical data on NAYZILAM® (midazolam) nasal spray CIV and BRIVIACT® (brivaracetam) CV in addition to epilepsy-related health economics outcomes research


Atlanta, Ga., June 24, 2020: UCB today announced six posters selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting, available online via the 2020 AAN Science Highlights virtual platform, which replaced the in-person event previously cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.

Jun

22

Celebrating MG Awareness Month, Together From Afar

Although this June may look and feel different from years past, we’re just as excited to spread awareness together with the myasthenia gravis (MG) community in celebration of Myasthenia Gravis (MG) Awareness Month. In light of the impact coronavirus is having on people around the world, especially people with MG who may be immunocompromised, we’re looking forward to connecting and celebrating in a virtual way.

Jun

19

UCB Statement on Racism and Racial Injustice

Over the last several weeks, UCB has shared deep concern and sadness about the state of racial injustice and heinous acts of violence against Black Americans happening in our country. We remain committed to living our Patient Value Principles to respect all people and to embrace diversity of thought, experience, and background. At UCB, we do not tolerate racism and racial injustice in any form.

Jun

17

Bringing Human Connection to Immunology Patients During COVID-19

UCB has been making ongoing adjustments to ensure continuous care for patients, including people living with immune-mediated inflammatory diseases during this time of great isolation. Hear more from UCB's Head of U.S. Immunology, Camille Lee, about our efforts to better support patients during this time.